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Wearable devices can predict the outcome of standardized
6-minute walk tests in heart disease
Charlotte Schubert 1,2, Gareth Archer3, Jo M. Zelis 4, Sarah Nordmeyer1, Kilian Runte1, Anja Hennemuth 1,5, Felix Berger 2,5,
Volkmar Falk 5,6,7,8, Pim A. L. Tonino4, Rod Hose3, Herman ter Horst9, Titus Kuehne 1,2,5 and Marcus Kelm 1,2,10✉
Wrist-worn devices with heart rate monitoring have become increasingly popular. Although current guidelines advise to consider
clinical symptoms and exercise tolerance during decision-making in heart disease, it remains unknown to which extent wearables
can help to determine such functional capacity measures. In clinical settings, the 6-minute walk test has become a standardized
diagnostic and prognostic marker. We aimed to explore, whether 6-minute walk distances can be predicted by wrist-worn devices
in patients with different stages of mitral and aortic valve disease. A total of n= 107 sensor datasets with 1,019,748 min of
recordings were analysed. Based on heart rate recordings and literature information, activity levels were determined and compared
to results from a 6-minute walk test. The percentage of time spent in moderate activity was a predictor for the achievement of
gender, age and body mass index-specific 6-minute walk distances (p < 0.001; R2= 0.48). The uncertainty of these predictions is
demonstrated.
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INTRODUCTION
The 6-minute walk test is a widely used measure of exercise
tolerance and a predictor of patient-centred outcomes. In patients
with cardiovascular disease, including valve disease, current
guidelines advise considering exercise capacity for diagnostics
and treatment planning1,2. Wrist-worn devices are constantly
improving and have become available to large parts of the
population. Today’s sensors typically include mechanical and
optical methods to measure activity and heart rate that provide
information on individual exercise intensities and gross energy
expenditure.
Previous studies have identified wrist-worn devices, acceler-
ometers and pedometers as effective tools to increase patients'
daily activity3,4 and have explored the associations between
physical activity, cardiovascular events and risk factors5–8. Whereas
many devices are designed to record activity, it has not been
studied if wrist-worn devices can predict 6-minute walk tests to
accurately assess exercise capacity and enable comparisons
between patients.
The 6-minute walk test has been clinically validated and has
been used to determine the effects of therapeutic interven-
tions9,10 and prognosis11,12. Although standardized medical
exercise tests such as 6-minute walk tests are easy to perform,
they still require visiting healthcare services. Wrist-worn devices
could offer the advantage of broad availability and may allow
performing measurements at home and during everyday activity.
Additionally, wearable devices can provide continuous monitoring
which enables trends to be identified, making it easier to
distinguish the deteriorating patient from the patient that is
doing well.
We, therefore, aimed to analyse if 6-minute walk test results can
be predicted by heart rate-based activity profiles obtained from
wrist-worn devices in combination with literature data in patients
with valvular heart disease.
RESULTS
Baseline characteristics and differences between centres
In total, N= 123 datasets from 91 patients with mitral or aortic
valve disease were acquired between March 2017 and October
2018. Of those, n= 9 datasets were excluded due to tachycardic
atrial fibrillation, and n= 7 due to unavailability of 6-minute walk
test data, resulting in a total of n= 107 included datasets and
1,019,748min of recordings from 84 patients at both sites (Fig. 1).
Accordingly, the average recording time of one dataset was 159 h.
A total of n= 23 patients contributed a second dataset at the time
of a 6-month clinical follow-up after undergoing a valve
replacement procedure. As patient characteristics had changed,
these patients are represented by two datasets. Baseline
characteristics of included datasets are shown in Table 1. Disease
severity according to classification standards was mild in 70
(65.4%), moderate in 18 (16.8%) and severe in 19 (17.8%) patients.
From all heart rate-based activity levels, time was mostly spent in
light activity (51.1%, interquartile range (IQR) 44.8–55.9%). Median
6-minute walk distances were 517m (IQR 409–581 m). The median
percentages of achieved target 6-minute walk distances were 97%
(IQR 83.69–109.78%). Targets are patient-specific based on patient
age, gender and body mass index (BMI). Parameters of activity are
shown in Table 2.
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Of all included datasets, 55 originated from German Heart
Centre Berlin and 52 from Sheffield Teaching Hospitals. Patients
from both study centres did not differ in daily time spent in
different levels of activity and disease severity. Patients from the
German Heart Centre Berlin were younger (62.15 vs. 68.38 years,
p= 0.012), had lower BMIs (26.39 vs. 28.19 kg/m2, p= 0.018),
higher number of steps per day (29,883.98 vs. 24,931.41 steps, p=
0.01), higher 6-minute walk distances (554.27 vs. 420.13 m, p <
0.001) and achieved higher percentages of their target 6-minute
walk distances in meters (103.68% vs. 87.16%, p < 0.001).
Correlation between heart rate- and motion sensor-based activity
counts
Initially, associations between pairs of activity measures were
evaluated. Correlations were found between heart rate-based
combined daily time spent in light/moderate activity and steps
(R2= 0.422, p < 0.001, Fig. 2d) as well as activity counts (R2= 0.539,
p < 0.001, Fig. 2c), both obtained from motion sensor data of the
device. There were also correlations between heart rate-based
daily time spent in moderate activity alone and step counts (R2=
0.08, p= 0.003, Fig. 2b) as well as activity counts (R2= 0.087,
p= 0.002, Fig. 2a).
The percentage of time spent in moderate activity correlated
with the absolute 6-minute walk distances (R2= 0.059, p= 0.012,
Fig. 3a). No correlations were found between combined time
spent in light/moderate activity and the 6-minute walk distances
(R2= 0.005, p= 0.472, Fig. 3b).
For the correlations shown in Fig. 3, other patient-specific data
(anthropometrics, demographics) were not considered, and thus
they only assess the correlation between pairs of variables.
Prediction of 6-minute walk test outcomes
In a logistic regression model, the combination of the time spent
in moderate activity, age and the type of disease were predictors
for the achievement of patient-specific target 6-minute walk
distances (overall model’s p < 0.001 (pseudo-) R2= 0.16). The odds
ratios were 1.54 (95% CI 1.04–2.3, p= 0.037) for percent time
spent in moderate activity, 1.05 (95% CI 1.01–1.1, p= 0.007) for
each year in age, 0.1 (95% CI 0.02–0.56, p= 0.009) for presence of
aortic stenosis and 0.27 (95% 0.09–0.82, p= 0.021) for presence of
mitral regurgitation. The area under the ROC curve was 75.9%,
with 71% of all cases correctly classified regarding achievement or
failure to achieve target 6-minute walk distances (reference
distances of healthy individuals), resulting in a sensitivity of 65%
and a specificity of 77% for the combined model. The use of beta
blockers (95% CI 0.38–2.6, p= 0.985) as well as NYHA classes
(NYHA II 95% CI 0.67–6.38, p= 0.204, NYHA III 95% CI 0.67–6.38,
p= 0.341, NYHA IV 95% CI 0.05–24.26, p= 0.972) did not show a
123 Heart rate profiles
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Fig. 1 STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology Initiative) flow diagram. Overview
illustrating the selection of datasets and reasons for exclusion.
Table 1. Baseline characteristics.
Parameter N= 107
Age (years) 66 (56–75)
Male sex (n) 65 (60.7%)










Hypertension (n) 67 (62.6%)
Diabetes mellitus (n) 11 (10.3%)
Smoker (n) 15 (14%)
Previous smoker (n) 44 (41.1%)
Intermittent atrial fibrillation (n) 11 (10.3%)
Permanent atrial fibrillation (n) 12 (11.2%)
Beta blockers (n) 58 (54.2%)
Diuretics (n) 47 (44%)
ARB or ACE-I (n) 59 (55.2%)
Calcium antagonists (n) 13 (12.1%)
WHOQOL-D1(Physical) 53 (44–56)
WHOQOL-D2 (Psychological) 63 (56–69)
WHOQOL-D3 (Social relationships) 69 (56–81)
WHOQOL-D4 (Environment) 75 (69–88)
Aortic valve disease (n) 38 (35.5%)
Mitral valve disease (n) 69 (64.5%)
N= 38
Surgical aortic valve replacement (n)
Transcatheter aortic valve replacement (n)
21 (55.3%)5 (13.2%)
N= 69
Mitral valve repair (n) 41 (59.4%)
Mitral valve replacement (n) 2 (2.9%)
Data are expressed as median (interquartile range) or absolute numbers
(percentage).
ARB angiotensin II receptor blockers, ACE-I angiotensin-converting enzyme
inhibitors, WHOQOL World Health Organization Quality of Life BREF score.
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relevant influence within the model. Moreover, running the model
without including information on the percentage of time spent in
moderate activity did not result in a valid prediction. The
probability of achieving target 6-minute walk distances for
different percentages of time spent in moderate activity is shown
in Fig. 4.
In a robust regression model the time spent in moderate
activity in combination with gender, age and BMI as covariates
were able to predict 6-minute walk distances (p < 0.001, R2= 0.48).
Each additional percentage of moderate activity led to an increase
in 6-minute walk distance of 10.86 m (95% CI 1.38–20.44, p=
0.027), every additional year of life resulted in a decrease in
6-minute walk distances (−4.92 m, 95% CI −6.71 to −3.12, p <
0.001) and each kg/m2 of BMI in a decrease of −7.42m (95% CI
−12.45 to −2.39, p= 0.004). On average, women achieved 77.2 m
(95% CI −121.96 to −32.43, p= 0.001) less than men. Beta blocker
therapy was included in the model as a baseline covariate and was
without relevant impact on patient-specific 6-minute walk
distances (95% CI −32–54 to 42.68, p= 0.79). Compared to the
minimally detectable changes (MDC) of the 6-minute walk test at
95% confidence intervals in frail older adults of 28.1 m13, a
systematic review reporting the minimal clinically important
difference of the test to range from 14 to 30.5 m14, the standard
deviations of our model-based predictions were between 12.53
and 49.98 m in men and between 18.72 and 57.83 m in women.
According to the time spent in moderate activity, gender, age and
BMI, specific predicted 6-minute walk distances in meters
(including their uncertainty) are provided in Tables 3 and 4.
Table 2. Parameters of activity.
Parameter N= 107
Steps per day 26,258 (20,674.7–34,160.5)
Activity count per day 2,933,540 (2,329,200–3,573,280)
Light activity (%) 51.1 (44.8–55.9)
Moderate activity (%) 0.8 (0.3–1.5)
High activity (%) 0 (0–0.1)
Sleep/rest (%) 47.4 (42.9–52.9)
Activity heart rate index 0.05 (0.03–0.06)
Six-minute walk distance (m) 517 (409–581)
Achieved percentage of target 6-
minute walk distance (%)
96.71 (83.69–109.78)
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Fig. 2 Relationship between steps and activity counts, recorded by the device at different heart rate-based activity levels. a Daily activity
counts measured by the wrist-worn device plotted against daily time spent in moderate activity (R2= 0.087, p= 0.002). b Daily steps plotted
against daily time spent in moderate activity (R2= 0.08, p= 0.003). c Daily activity counts plotted against time spent in combined light and
moderate activity (R2= 0.539, p < 0.001). d Daily steps plotted against time spent in combined light and moderate activity (R2= 0.422,
p < 0.001). AU arbitrary units.
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DISCUSSION
In this study, we used heart rate monitoring from wearables in
combination with literature-based reference data to determine
the daily amount of time spent in different levels of activity. The
time spent in moderate activity was able to predict outcomes of a
6-minute walk test in patients with valvular heart disease. In
combination with information on a patient’s gender, age, BMI and
disease type, absolute 6-minute walk test distances as well as the
probability of achieving target 6-minute walk distances can be
predicted (Fig. 5). Furthermore, the uncertainty of these model-
based predictions is demonstrated and overlapped with the
minimal detectable changes and the minimal clinically important
differences of the 6-minute walk test.
Exercise testing in cardiology can help to distinguish sympto-
matic patients, provide prognostic information before therapeutic
interventions and thus can play an integral role in decision-
making processes15. The 6-minute walk test is an inexpensive and
feasible method to be performed in the clinical and ambulatory
setting. Nevertheless, it is limited to submaximal exercise levels
and does not provide information on causes of limiting factors,
which has remained a more exclusive domain of ergometric
tests16. However, especially with bicycle ergometers, maximal
exercise levels may not be achieved due to general exhaustion or
fatigue of the quadriceps muscle17. Both the 6-minute walk test
and ergometric exercise tests typically require special equipment
and trained personnel and are vastly limited in children and
patients with frailty. Both methods, furthermore, strongly depend
on the patient's motivation.
In aortic stenosis and mitral regurgitation, a decrease of exercise
capacity can indicate the onset of symptoms as well as a
worsening of the haemodynamic status and it is therefore
commonly regarded as an indication for intervention1,2. Its early
recognition can be an important determinant for the outcome, as
arrhythmia, sudden cardiac death and heart failure can occur
when symptomatic patients are left untreated18–21. Hence,
additional ways for an uncomplicated evaluation of exercise
capacity are of potential clinical value.
Activity in this study was identified using daily heart rate
profiles obtained by a wrist-worn device. Previous studies
assessing the accuracy of such devices have found an overall
high accuracy for measuring heart rate22,23 as well as steps24–26,
whereas different intensity levels24 and energy expenditure25,26
could only be determined imprecisely. The combined time spent
in light/moderate activity correlates with daily steps (Fig. 2d).
However, the results of the present study indicate that solely
determining overall physical activity is not sufficient to predict
exercise capacity. Only with quantification of the specific time
spent in moderate activity, 6-minute walk test outcomes were
effectively predicted. In contrast, the combined time spent in
R
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Fig. 3 Relationship between 6-minute walk distances and the percent time spent at different heart rate-based activity levels (without
consideration of anthropometric and demographic parameters). a Six-minute walk distances in meters plotted against daily time spent in
moderate activity (R2= 0.059, p= 0.012). b Six-minute walk distances in meters plotted against time spent in combined light and moderate
activity (R2= 0.005, p= 0.472). m meters.
Moderate: activity 4 %
Moderate: activity 0 %





















































40 45 50 55 60 65 70 75 80 85 90
Age [years]
Fig. 4 Probabilities of achieving target 6-minute walk distances
dependent on age. Curves represent different percentages (0, 4 and
8%) of daily time spent in moderate activity.
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light/moderate activity is dominated by light activity. These
measures did not show a correlation to the 6-minute walk
distances and even when combined with demographic and
anthropometric data it was unable to determine these outcomes.
In our study cohort, the probability of achieving target 6-minute
walk test goals of a reference population increased with age (Fig.
4). This effect may at least in parts be attributed to shorter overall
target distances in the elderly in combination with a tendency for
less activity. At the same time, older patients of our study cohort
performed better than younger patients when compared to
clinically used reference populations of the same age16. Never-
theless, patients with a higher percentage of moderate activity
performed better within their age group. This also underlines that
anthropometric and demographic data alone cannot accurately
predict BMI, age and gender-specific 6-minute walk test outcomes
in a cohort of patients with heart disease, as individual conditions
are not considered. Therefore, the robust regression model
combines moderate activity with demographic and anthropo-
metric data to predict individual 6-minute walk distances. High
activity occurred only sporadically within the observed patient
population and can also include errors due to phases of
tachycardia, such as in atrial fibrillation.
Besides identifying arrhythmic events27, a heart rate-based
approach for evaluating exercise capacity may have the advan-
tage of enabling continuous surveillance during everyday life, e.g.,
for telemonitoring. A large amount of data gained from
telemonitoring could, in turn, be used to further improve the
method and reduce its statistical uncertainty. The advantages of
continuous monitoring of exercise capacity may be particularly
well illustrated by the example of asymptomatic aortic stenosis,
where the timing of intervention is still controversial21,28–30. While
current guidelines strongly advise for surgical intervention as soon
as symptoms occur, in asymptomatic patients it is only
recommended in cases of severe stenosis1,2. However, symptoms
are prone to subjective interpretation and may not always be
perceived by patients in the same way29,30. Additionally, monitor-
ing moderate activity may also be beneficial in settings where
physical activity is restricted to avoid symptoms. Koehler et al.31
have recently found that telemedical monitoring of heart failure
patients can help to reduce all-cause mortality and hospital days
due to unplanned cardiovascular reasons. The continuous
monitoring of exercise capacity could additionally help to detect
gradual clinical worsening and should, therefore, be further
evaluated to better understand the potential benefits of such
broadly available information for disease detection and therapy
planning.
In cardiopulmonary exercise testing, exercise is usually quanti-
fied by an externally set workload. A heart rate-based approach,
however, relies on the interpretation of a surrogate where
literature evidence is used to identify activity states.
Finally, we acknowledge that this study has certain limitations.
To determine resting heart rate, activity sensors data of the device
were used. The paroxysmal occurrence of tachycardic atrial
fibrillation, especially common in the older population32, may
potentially influence the heart rate-based analysis of activity. To
reduce the influence of atrial fibrillation on measurements, heart
rate profiles have been scanned for tachycardia and if present,
were excluded. However, it cannot be certain that datasets with
short periods of atrial fibrillation may still be included. Addition-
ally, moderate activity itself can trigger relevant tachycardia. The
combined simultaneous use of heart rate sensors, actometers and
novel integrated electrocardiographic sensors may help to better
detect such events and to distinguish between tachyarrhythmia
and activity.
The influence of age, medication and physical fitness on the
resting heart rate may be a limitation for categorizing activity
based on heart rate data. Therefore, the use of beta blockers was
included as a covariate within the models and was shown to be
without relevant impact for the achievement of target 6-minute
walk distances or absolute distances. Furthermore, the thresholds
for activity levels are based on individual resting heart rates.
Consequently, for patients with low resting heart rates, e.g., due to
beta blockers or high fitness level, the thresholds for activity levels
would be correspondingly lower.
Compared to large-scale physical activity data33, the average
number of steps per day in our cohort was high and may in parts
be attributed to an increased awareness that can influence daily
activity. Additionally, the large-scale datasets were acquired from
mobile phones, that are not always carried. In contrast, the wrist-
worn devices had a high wearing time, which has a direct impact
on the number of recorded steps.
When determining exercise capacity based on daily physical
activity, it should be considered that externals factors can affect
activity. For example, exceptional situations or events occur during
measurement periods, and thus daily activity can be influenced,
not reflecting the individual exercise capacity. By extending
measurement periods and patient counts, this confounder could
be further limited. Several other factors including orthopaedic or
mental diseases can influence everyday physical activity34,35.
However, long-term changes in daily physical activity are
commonly known to also result in changes in exercise capacity36.
Higher sample sizes may help to further improve the model and
reduce variances.
Fig. 5 Graphical summary. Step-by-step presentation of the concept for predicting 6-minute walk distances based on daily recordings from
wrist-worn devices in combination with demographic and anthropometric data.
C. Schubert et al.
6
npj Digital Medicine (2020)    92 Scripps Research Translational Institute
The 6-minute walk test has become a widely used prognostic
marker of patient-centred outcomes including death or hospita-
lization37. Its ability to determine exercise capacity can be
influenced by several individual physical and psychological
factors, including pain, motivation and co-morbidities. Although
it is considered to be a standardized test, its variability can be
substantial even in healthy populations. As a goodness-of-fit
indicator, R2 values of the robust regression model were
approximately 0.5 within our cohort. In line with these findings,
an inherently great amount of unexplainable variation can
typically be found in exercise testing. In healthy subjects,
coefficients of determination (R2) similar to our values have been
reported when comparing the expected (equation-based refer-
ence values) and the actually achieved walking distances38.
Additionally, the uncertainty of the model-based predictions
(provided in Tables 3 and 4) overlapped with the minimal
clinically important differences of the 6-minute walk test. Hence,
we consider the findings in our disease-specific cohort to be
clinically meaningful and vastly within the limitations of the 6-
minute walk test14, although the amount of unexplained variation
in this clinical standard method can be high.
Heart rate-based activity levels and the model’s output were not
directly tested against more objective variables of functional
capacity tests or morbidity/mortality outcomes. Therefore, further
studies are needed to assess, how these measures translate into
patient-specific outcomes. Some studies assessing 6-minute walk
tests have found an association of results from cardiopulmonary
exercise testing and the 6-minute walk test39–41, whereas others
did not find the 6-minute walk test to be a reliable measure of
exercise capacity42. Further studies testing the assessment of
exercise capacity, using heart rate data obtained from wrist-worn
devices, against cardiopulmonary exercise testing might be
needed to support its validity. Furthermore, studies including
other patient groups are needed to verify the method's
applicability for other diseases. More datasets with a longer
recording time could further reduce statistical uncertainty.
In summary, we were able to demonstrate that wrist-worn
devices can be of use for predicting a patient's 6-minute walk test
outcome, with uncertainties overlapping to the minimal clinically
important differences and the MDC of the 6-minute walk test
itself. The daily time spent in moderate activity was determined
based on heart rate data obtained from these wearable devices. It
was predictive for 6-minute walk distances and achievement of
patient- (gender, age and BMI) specific target 6-minute walk
distances, an established diagnostic and prognostic marker.
Further studies in larger cohorts and a variety of disease groups
are required to improve the method’s accuracy and to investigate
if continuous recordings can provide helpful additional informa-
tion for diagnostic processes and therapy planning.
METHODS
Study population
The present study was part of the “EurValve” research initiative, focusing
on decision support in patients with valvular heart disease. The project’s
aim was to implement and test, in a relevant clinical target cohort, a
decision support system (DSS) for aortic and mitral valve replacement and
repair. The main component of the DSS was a combined 0D model of the
cardiovascular system that includes modification options for valve repair
and replacement, aiming to predict the haemodynamic effects of different
types of treatment. The multi-centre study was conducted at three
European sites in the Netherlands, the United Kingdom and Germany. In all
recruited patients, clinical routine data were assessed and included
demographics, anthropometrics, medical history and functional cardiac
imaging. Patients with aortic stenosis, mitral regurgitation and mixed
valvular heart disease recruited at Deutsches Herzzentrum Berlin (DHZB,
German Heart Centre Berlin) and the Sheffield Teaching Hospitals were
assessed using a Philips health watch (DL8791, Philips, Stamford, CT, USA).
The device is licensed as a medical product in Europe. Heart rate as well as
steps and activity counts from wrist movement was recorded.
The study protocol included wearing the device during everyday life for
at least 23 h and performing a 6-minute walk test. Datasets were excluded
if the heart rate-based analysis of daily activity was affected by tachycardic
atrial fibrillation or if no 6-minute walk test was conducted. Patients were
included at different stages and time points during the treatment process
(before and/or after treatment).
The primary comparison was between the amount of time spent at
different levels of activity each day, based on heart rate and 6-minute walk
distances. Secondarily, daily activity was compared to the achievement of
target 6-minute walk distances. All procedures followed the ethical
guidelines of the 1975 Declaration of Helsinki and were approved by the
local Ethical Committee at both sites (Ethikkomission Charité—Univer-
stätsmedizin Berlin: EA2/093/16, NHS Health Research Authority: 17/LO/
0283). Written informed consent was obtained from all included patients.
Due to ethical regulations, untreated patients with severe aortic stenosis
were not included at German Heart Centre Berlin. The study complied with
the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Statement. The study has been registered on ClinicalTrials.gov
(NCT04068740).
Six-minute walk test
The six-minute walk test was conducted before providing the patient with
a device and was performed according to current guidelines16 shortly
before the device recordings. The patient-specific target distance
depending on gender, age and BMI was calculated using the established
formula “6-minute walk distance= 1140m− (5.61 × BMI)− (6.94 × age)”
for men and “6-minute walk distance= 1017m− (6.24 × BMI)− (5.83 ×
age)” for women43.
Heart rate-based measurements of physical activity
The average heart rate as well as the total number of steps and activity
counts were computed for each minute. Activity is a measure of
accelerometery counts data obtained from the wrist-worn device. All data
were analysed by an automated software tool to identify time spent at
different levels of activity. Sleep and rest were determined based on steps
and activity counts during recordings. Rest was defined as one or no steps
per minute and an activity count below 475 arbitrary units (AU) per minute;
sleep as an activity count below 70 AU.
The average heart rate during time spent resting while wearing the
device was defined as the resting heart rate. All activity levels were then
determined by changes in heart rate. Based on a meta-analysis of
physiologic heart rate changes during different levels of activity44 and the
identified resting heart rate, the level of activity was determined for each
data point. An increase of the heart rate between 31 and 49 b.p.m. above
resting heart rate was defined as light, between 50 and 88 b.p.m. as
moderate and above 88 b.p.m. as high activity44.
Statistical analysis
Continuous data are expressed as median and interquartile range (IQR,
Q1–Q3) unless stated otherwise. Categorical data are presented as
frequencies and percentages (%). Data distribution was tested using
Shapiro–Wilk and Shapiro–Francia tests. A logistic regression model with
continuous and binary patient-specific covariates (age, presence of aortic
valve disease and presence of mitral valve disease, use of beta blockers)
was used to evaluate the predictive quality of the percent time spent in
moderate activity on binary outcome measures (achievement of target 6-
minute walk distances). Additional to patient-specific anthropometric and
demographic characteristics, both disease conditions were included as
binary covariates to control for possible unobserved variables within the
disease groups. The rationale for including these conditions in a single
model instead of testing in separate models was the concept of general
applicability of the method across different groups of valvular heart
disease. Robust regression was used to assess multifactorial effects on 6-
minute walk distances with consideration of outliers. Based on the robust
regression, R2 values (as a goodness-of-fit measure) and predictive margins
with standard deviations were calculated and plotted to visualize the
combined effects of age, gender and BMI. Stata version 15.1 was used for
statistical analysis. Interpretation of our findings followed the advice by the
American Statistical Association45. MFPIGEN package was used to
investigate the interaction between each pair of covariates and both
predictive models were built without interactions.
C. Schubert et al.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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